Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Karl-Erik Andersson. (2013) Treatment of lower urinary tract symptoms: Agents for intraprostatic injection. Scandinavian Journal of Urology 47:2, pages 83-90.
Read now
Read now
Hashim Hashim & Paul Abrams. (2010) Emerging drugs for the treatment of benign prostatic obstruction. Expert Opinion on Emerging Drugs 15:2, pages 159-174.
Read now
Read now
Mohammadreza Nikoobakht, Azar Daneshpajooh, Hamed Ahmadi, Farshad Namdari, Maedeh Rezaeidanesh, Shahab Amini & Gholamreza Pourmand. (2010) Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: Initial experience with Dysport™. Scandinavian Journal of Urology and Nephrology 44:3, pages 151-157.
Read now
Read now
Articles from other publishers (26)
Hann-Chorng Kuo. (2022) Clinical Application of Botulinum Neurotoxin in Lower-Urinary-Tract Diseases and Dysfunctions: Where Are We Now and What More Can We Do?. Toxins 14:7, pages 498.
Crossref
Crossref
Grégoire Robert, Aurélien Descazeaud, Gilles Karsenty, Christian Saussine, Abdel-Rahmène Azzouzi, Alexandre de la Taille, François Desgrandchamps, Antoine Faix, Marc Fourmarier, Aurore Georget, Antoine Benard & Nicolas Barry Delongchamps. (2018) Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial. World Journal of Urology 36:6, pages 921-929.
Crossref
Crossref
Angelo Totaro, Francesco Pinto, Dario Pugliese, Matteo Vittori, Marco Racioppi, Nazario Foschi, Pier Francesco Bassi & Emilio Sacco. (2018) Intraprostatic botulinum toxin type “A” injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: A randomized, double-blind, controlled trial using urodynamic evaluation. Neurourology and Urodynamics 37:3, pages 1031-1038.
Crossref
Crossref
Nicolas B. Delongchamps. 2018. Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia
289
303
.
Cheng-Ling Lee & Hann-Chorng Kuo. (2017) Botulinum toxin A treatment for lower urinary tract symptoms/benign prostatic hyperplasia. Urological Science 28:3, pages 119-122.
Crossref
Crossref
G. Magistro, C. G. Stief & C. Gratzke. (2016) Minimal-invasive Therapie des benignen ProstatasyndromsMinimally invasive treatment of benign prostatic hyperplasia. Der Urologe 55:11, pages 1419-1432.
Crossref
Crossref
Jia-Fong Jhang & Hann-Chorng Kuo. (2016) Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action. Toxins 8:4, pages 120.
Crossref
Crossref
David Moore, Joshua Cohn & Roger Dmochowski. (2016) Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature. Toxins 8:4, pages 88.
Crossref
Crossref
T. Bschleipfer, T. Bach, R. Berges, K. Dreikorn, C. Gratzke, S. Madersbacher, M.-S. Michel, R. Muschter, M. Oelke, O. Reich, C. Tschuschke & K. Höfner. (2015) S2e-Leitlinie der Deutschen UrologenS2e guideline of the German urologists. Der Urologe 55:2, pages 195-207.
Crossref
Crossref
Yuan-Hong Jiang, Chun-Hou Liao & Hann-Chorng Kuo. (2015) Current and potential urological applications of botulinum toxin A. Nature Reviews Urology 12:9, pages 519-533.
Crossref
Crossref
Giuseppe Magistro, Christian G. Stief & Christian Gratzke. (2015) New intraprostatic injectables and prostatic urethral lift for male LUTS. Nature Reviews Urology 12:8, pages 461-471.
Crossref
Crossref
Jung Jun Kim, Deok Hyun Han, Hyun Hwan Sung, Seol Ho Choo & Sung Won Lee. (2014) Efficacy and tolerability of tamsulosin 0.4 mg in Asian patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia refractory to tamsulosin 0.2 mg: A randomized placebo controlled trial. International Journal of Urology 21:7, pages 677-682.
Crossref
Crossref
Michael B. Chancellor, Elie Elovic, Alberto Esquenazi, Markus Naumann, Karen R. Segal, Giampietro Schiavo, Christopher P. Smith & Anthony B. Ward. (2013) Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions. Toxicon 67, pages 129-140.
Crossref
Crossref
Michael Marberger, Emmanuel Chartier-Kastler, Blair Egerdie, Kyu-Sung Lee, Joachim Grosse, Denise Bugarin, Jihao Zhou, Anand Patel & Cornelia Haag-Molkenteller. (2013) A Randomized Double-blind Placebo-controlled Phase 2 Dose-ranging Study of OnabotulinumtoxinA in Men with Benign Prostatic Hyperplasia. European Urology 63:3, pages 496-503.
Crossref
Crossref
T. Bschleipfer, T. Bach, C. Gratzke, S. Madersbacher & M. Oelke. (2013) Intraprostatische Injektionstherapien beim benignen ProstatasyndromIntraprostatic injection therapy in patients with benign prostatic syndrome. Der Urologe 52:3, pages 354-358.
Crossref
Crossref
Yue-Chen Kuo & Hann-Chorng Kuo. (2013) Botulinum toxin injection for lower urinary tract dysfunction. International Journal of Urology 20:1, pages 40-55.
Crossref
Crossref
Laetitia M.O. de Kort, Esther T. Kok, Trudy N. Jonges, Peter F.W.M. Rosier & J.L.H. Ruud Bosch. (2012) Urodynamic Effects of Transrectal Intraprostatic Ona botulinum Toxin A Injections for Symptomatic Benign Prostatic Hyperplasia. Urology 80:4, pages 889-893.
Crossref
Crossref
Cristobal Marchal, Juan E. Perez, Bernardo Herrera, Francisco J. Machuca & Maximino Redondo. (2011) The use of botulinum toxin in benign prostatic hyperplasia. Neurourology and Urodynamics 31:1, pages 86-92.
Crossref
Crossref
Yukio Homma, Momokazu Gotoh, Osamu Yokoyama, Naoya Masumori, Akihiro Kawauchi, Tomonori Yamanishi, Osamu Ishizuka, Narihito Seki, Toshiyuki Kamoto, Atsushi Nagai & Seiichiro Ozono. (2011) JUA clinical guidelines for benign prostatic hyperplasia. International Journal of Urology 18:11, pages e1-e33.
Crossref
Crossref
Yukio Homma, Momokazu Gotoh, Osamu Yokoyama, Naoya Masumori, Akihiro Kawauchi, Tomonori Yamanishi, Osamu Ishizuka, Narihito Seki, Toshiyuki Kamoto, Atsushi Nagai & Seiichiro Ozono. (2011) Outline of JUA clinical guidelines for benign prostatic hyperplasia. International Journal of Urology 18:11, pages 741-756.
Crossref
Crossref
Altaf Mangera, Karl-Erik Andersson, Apostolos Apostolidis, Chris Chapple, Prokar Dasgupta, Antonella Giannantoni, Stavros Gravas & Stephan Madersbacher. (2011) Contemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA). European Urology 60:4, pages 784-795.
Crossref
Crossref
João Silva, Rui Pinto, Tiago Carvalho, Francisco Botelho, Pedro Silva, Carlos Silva, Francisco Cruz & Paulo Dinis. (2010) Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. BJU International 107:12, pages 1950-1954.
Crossref
Crossref
Emmanuel Chartier-Kastler, Ulrich Mehnert, Pierre Denys & Francois Giuliano. (2011) Botulinum neurotoxin A for male lower urinary tract symptoms. Current Opinion in Urology 21:1, pages 13-21.
Crossref
Crossref
Henry P. Gottsch, Claire C. Yang & Richard E. Berger. (2010) A Review of Botulinum Toxcin Use for Chronic Pelvic Pain Syndrome. Current Urology Reports 11:4, pages 265-270.
Crossref
Crossref
Athanassios Oeconomou & Helmut Madersbacher. (2010) Botulinum neurotoxin A for benign prostatic hyperplasia. Current Opinion in Urology 20:1, pages 28-36.
Crossref
Crossref
João Silva, Rui Pinto, Tiago Carvalho, Francisco Botelho, Pedro Silva, Rui Oliveira, Carlos Silva, Francisco Cruz & Paulo Dinis. (2009) Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. BMC Urology 9:1.
Crossref
Crossref